Shanghai Pudong R&D and Manufacturing Site Global Presence - PORTON

CN
Home/About Us/Global Presence

Shanghai Pudong R&D and Manufacturing Site

It operates R&D and manufacturing facilities, offering one-stop Biologics and Conjugates CDMO services from Drug Substance (DS) to Drug Product (DP).
Contact Us
1st Floor, Building 3, 201 Huashen Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 200131, China

    2000+m2PD & AD Labs

    The center includes facilities such as the Antibody Drug Substance Process Development Center, ADC Conjugation Process Development Center, Antibody and ADC Formulation Process Center, and Quality Research and Testing Center.

    3000+m2GMP Mfg

    We have GMP manufacturing capabilities and can provide comprehensive ADC drug DS+DP integrated services to our clients.

Services

Biologics and Conjugates Drugs
Biologics and Conjugates Drugs
As a subsidiary of Porton Pharma Solutions, a globally recognized CDMO, Porton Biologics and Conjugates CDMO Platform offers comprehensive, one-stop drug development and manufacturing services for biologics and conjugates, including ADCs, AOCs, PDCs, and more.

More

Facilities

PD & AD Labs GMP Mfg.
PD & AD Labs
  • Antibody DS PD Labs
  • Antibody DP PD Labs
  • Exclusive ADC Conjugation Labs
  • AD Labs
GMP Mfg.
  • Antibody DS Mfg
  • Antibody DP Mfg
  • Bioconjugation and Purification
  • ADC Lyophilization
  • QC and Warehouses

One Porton One Quality

Compliance standards, Continuous improvement, Customer oriented
Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.

Case Studies

Overview and Case Study of Antibody Oligonucleotide Conjugates (AOC)

Overview and Case Study of Antibody Oligonucleotide Conjugates (AOC)

An ADC's Path to Market-Analysis of Difficulties and Key Points in ADC Process Scale up
Heterogeneous nucleation (HN)

Co-processing Series: 4. Heterogeneous nucleation (HN)
Adsorption

Co-processing Series: 3. Adsorption

ASD Amorphous Solid Dispersions

Co-processing Series: 2. ASD - How Co-Processing can replace Spray Drying

co-processing

Co-processing Series: 1. What is co-processing and how is the industry embracing it?

News

More

News2025-01-14

Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform

More

News2024-12-23

Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership

More

News2024-12-19

Porton Newsletter | Q4 2024 Recap

More

News2024-12-11

Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs

More

News2024-12-06

Porton Recognized as an Exemplary Case for Sustainable Development

More

News2024-12-06

Porton is thrilled to announce the launch of its newly redesigned official website

More

News2024-10-31

Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities

More

News2024-10-24

Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar

More

News2024-10-01

Porton Newsletter | Q3 2024 Recap

More
Become part of Porton' s community to access personalized insights and resources.
Subscribe To Our Mailing List
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review ourLegal Disclaimer terms and Porton Privacy.
US: (609) 860-1300
CN: (86) 23-8608-3200

ⓒ 2024 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200